Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$15.47 USD
+0.16 (1.05%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $15.47 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRNA 15.47 +0.16(1.05%)
Will VRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
Other News for VRNA
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma price target raised by $5 at Piper Sandler, here's why
Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy